SELVITA S.A. SER.B ZY-80
Selvita S.A. operates as a contract research organization worldwide. The company offers drug discovery services in the areas of AI-driven drug discovery, antibody drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, ADME/DMPK, in vitro and In Vivo pharmacology, translational re… Read more
SELVITA S.A. SER.B ZY-80 (787) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, SELVITA S.A. SER.B ZY-80 (787) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
SELVITA S.A. SER.B ZY-80 - Net Assets Trend (None–None)
This chart illustrates how SELVITA S.A. SER.B ZY-80's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SELVITA S.A. SER.B ZY-80 (None–None)
The table below shows the annual net assets of SELVITA S.A. SER.B ZY-80 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to SELVITA S.A. SER.B ZY-80's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
SELVITA S.A. SER.B ZY-80 Competitors by Market Cap
The table below lists competitors of SELVITA S.A. SER.B ZY-80 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NEX POINT
BK:NEX-R
|
$128.99 Million |
|
Vef AB
ST:VEFAB
|
$129.06 Million |
|
Selvita S.A.
WAR:SLV
|
$129.09 Million |
|
Shandong Teamgene Technology Co. Ltd. A
SHG:603151
|
$129.09 Million |
|
Shanghai Lianming Machinery Co Ltd
SHG:603006
|
$128.88 Million |
|
Symphony Limited
NSE:SYMPHONY
|
$128.85 Million |
|
Chison Medical Technologies Co Ltd
SHG:688358
|
$128.78 Million |
|
Eagle Financial Services Inc Common Stock
OTCQX:EFSI
|
$128.78 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SELVITA S.A. SER.B ZY-80's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares SELVITA S.A. SER.B ZY-80's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently SELVITA S.A. SER.B ZY-80 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares SELVITA S.A. SER.B ZY-80's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $10,792,710,184
- Average return on equity (ROE) among peers: -33.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SELVITA S.A. SER.B ZY-80 (787) | €- | N/A | N/A | $128.95 Million |
| Spermosens AB (publ) (9R5) | $23.64 Million | -27.17% | 0.09x | $517.28K |
| BML Inc (BMZ) | $81.13 Billion | 8.19% | 0.43x | $462.01 Million |
| Genomic Vision Société Anonyme (G09) | $3.07 Million | -162.85% | 1.21x | $711.54K |
| ICON Public Limited Company (IJF) | $1.85 Billion | 17.96% | 0.86x | $6.43 Billion |
| Adicon Holdings Limited (K0U) | $1.77 Billion | 2.65% | 1.64x | $138.53 Million |
| WuXi XDC Cayman Inc. (L74) | $1.48 Billion | 10.52% | 0.69x | $2.11 Billion |
| NanoRepro AG (NN6) | $57.61 Million | 51.59% | 0.37x | $16.84 Million |
| PERRIGO (PGO) | $24.67 Million | -167.93% | 0.99x | $6.37K |